NCT03164798

Serum BDNF Role as a Biomarker for Stroke Rehabilitation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 150 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: Female
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.

Detailed description

Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured. In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis. We will compare potential serum biomarkers with motor impairment in stroke patients

Conditions

• Stroke
• Biomarker
• Rehabilitation
• BDNF

Interventions

Type	Name	Description
PROCEDURE	Conventional inpatient rehabilitation	comprehensive inpatient rehabilitation for 2 weeks

Timeline

• Start date: 2017-02-01
• Primary completion: 2019-08-31
• Completion: 2019-12-31
• First posted: 2017-05-24
• Last updated: 2020-03-18

Locations

1 site across 1 country: South Korea